MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

4.04 96.12

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.04

Max

4.06

Schlüsselkennzahlen
By Trading Economics
Angestellte	26

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.2M 16M
Vorheriger Eröffnungskurs	-92.08
Vorheriger Schlusskurs	4.04

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Jan. 2026, 23:49 UTC

Wichtige Markttreiber

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. Jan. 2026, 21:12 UTC

Wichtige Markttreiber

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. Jan. 2026, 20:29 UTC

Wichtige Markttreiber

Chip Makers Gain After Trump Calls Off European Tariffs

21. Jan. 2026, 20:04 UTC

Wichtige Markttreiber

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. Jan. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. Jan. 2026, 22:39 UTC

Ergebnisse

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Jan. 2026, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. Jan. 2026, 21:19 UTC

Ergebnisse

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. Jan. 2026, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. Jan. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. Jan. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. Jan. 2026, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. Jan. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Jan. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. Jan. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. Jan. 2026, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. Jan. 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. Jan. 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Group Agrees to Buy Allfunds

21. Jan. 2026, 20:08 UTC

Ergebnisse

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. Jan. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. Jan. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. Jan. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. Jan. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. Jan. 2026, 19:24 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. Jan. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. Jan. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.